Product information

From Health Canada

No match found

No other product was found with the same active ingredient group.

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Pre Market

Current status date:

2017-03-16

Original market date: See footnote 1

Product name:

OPANA ER

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02383438

Product Monograph/Veterinary Labelling:

Date: 2016-06-21 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PALADIN PHARMA INC.
100 Blvd Alexis-Nihon, Suite 600
Saint-Laurent
Quebec
Canada H4M 2P2

Class:

Human

Dosage form(s):

Tablet (Extended-Release)

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Narcotic (CDSA I)

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N02AA NATURAL OPIUM ALKALOIDS

Active ingredient group (AIG) number:See footnote5

0107554004

List of active ingredient(s)
Active ingredient(s) Strength
OXYMORPHONE HYDROCHLORIDE 10 MG

Risk Management Plans See footnote 7

A Risk Management Plan (RMP) for this product was submitted.

Version 4.0.2
Date modified: